Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Impact of sequencing of CART vs bi-specific antibody on survival in relapsed/refractory large B-cell lymphoma: An analysis from the ABC consortium

Blood (2025) 146 (Supplement 1): 398.

https://doi.org/10.1182/blood-2025-398

Published: 2025

Journal Articles

Phase II, single-arm, open-label, multicenter study: Efficacy of adjunctive Bruton's tyrosine kinase inhibitor (BTKi) zanubrutinib and chimeric antigen receptor (CART) in aggressive B-cell non-hodgkins lymphoma (aNHL)

Reem Karmali, Carlos Galvez, Jane Winter, Shuo Ma, Bin Zhang, Ping Xie, Yangruijue (Anna) Ma, Ruohui Chen, Nirav Shah, Leo Gordon

Blood (2025) 146 (Supplement 1): 1010.

https://doi.org/10.1182/blood-2025-1010

Published: 2025

Journal Articles

Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium

Blood (2025) 146 (Supplement 1): 960.

https://doi.org/10.1182/blood-2025-960

Published: 2025

Journal Articles

Bispecific antibody vs non-bispecific antibody systemic therapy as immediate next line treatment after chimeric antigen receptor T-cell (CART) failure in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 4502.

https://doi.org/10.1182/blood-2025-4502

Published: 2025

Journal Articles

Real-world outcomes with bispecific antibody therapies for aggressive B-cell lymphomas in octogenarians

Blood (2025) 146 (Supplement 1): 3746.

https://doi.org/10.1182/blood-2025-3746

Published: 2025

Journal Articles

Real world comparison of commercial CAR T-cell constructs for the treatment of LBCL

Blood (2025) 146 (Supplement 1): 781.

https://doi.org/10.1182/blood-2025-781

Published: 2025

Journal Articles

Outcomes of patients with Relapsed/Refractory aggressive B-cell lymphoma receiving bispecific antibody therapy as monotherapy or in combination with targeted therapy

Blood (2025) 146 (Supplement 1): 4551.

https://doi.org/10.1182/blood-2025-4551

Published: 2025

Journal Articles

Socioeconomic disadvantage, as measured by area deprivation index (ADI), impacts survival in patients with relapsed/refractory aggressive lymphoma treated with CART

Blood (2025) 146 (Supplement 1): 6281.

https://doi.org/10.1182/blood-2025-6281

Published: 2025

Journal Articles

Tumor-Infiltrating Normal B Lymphocytes Have Remarkable Prognostic Effects and Are Crucial for Antitumor Immune Responses in Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 429.

https://doi.org/10.1182/blood-2023-179972

Published: 2023

Journal Articles

Diffuse Large B-Cell Lymphoma Has a Low Frequency of dMMR and High Frequencies of DNA Mismatch Repair Protein High Expression Associated with Lower T-Cell Infiltration

Blood (2023) 142 (Supplement 1): 6079.

https://doi.org/10.1182/blood-2023-178366

Published: 2023

Journal Articles

Tacrolimus Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients Receiving Concomitant Voriconazole.

Steven Trifilio, Judy Pi, Seema Singhal, Olga Frankfurt, Andrew Evens, Leo Gordon, Martin Tallman, Jane Winter, Stephanie Williams, Jayesh Mehta

Blood (2007) 110 (11): 4956.

https://doi.org/10.1182/blood.V110.11.4956.4956

Published: 2007

Journal Articles

Outcome of Relapse after Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) - The Effect of the Underlying Disease on Survival Following Relapse.

Seema Singhal, Olga Frankfurt, Andrew Evens, Leo Gordon, Martin Tallman, Stephanie Williams, Jane Winter, David Grinblatt, Lynne Kaminer, Jayesh Mehta

Blood (2007) 110 (11): 5020.

https://doi.org/10.1182/blood.V110.11.5020.5020

Published: 2007

Journal Articles

Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH) Following Rituximab Induction in Patients (pts) with Follicular B-Cell Lymphoma (FL): Progression Free Survival (PFS) at 4-Year Follow Up.

Omer Koc, MD, Charles Redfern, MD, Peter Wiernik, MD, Fred Rosenfelt, MD, Jane Winter, MD, Troy Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, John Hainsworth, MD, Thomas S. Lin, MD, PhD, Rene Castillo, MD, Nalini Janakiraman, MD, John Bender, PharmD

Blood (2007) 110 (11): 2567.

https://doi.org/10.1182/blood.V110.11.2567.2567

Published: 2007

Journal Articles

Submyeloablative Allografts for Hematologic Malignancies: Validation of a Prognostic Model Based on Pre-Transplant Variables.

Jayesh Mehta, Jane Winter, Martin Tallman, Leo Gordon, Stephanie Williams, Olga Frankfurt, Andrew Evens, David Grinblatt, Lynne Kaminer, Richard Meagher, Seema Singhal

Blood (2006) 108 (11): 3036.

https://doi.org/10.1182/blood.V108.11.3036.3036

Published: 2006

Journal Articles

Reduced-Intesity Allogeneic HSCT in Hematologic Malignancies: Influence of Underlying Diagnosis and Prior Autograft on Outcome.

Jayesh Mehta, Leo Gordon, Martin Tallman, Jane Winter, Stephanie Williams, Olga Frankfurt, Andrew Evens, David Grinblatt, Lynne Kaminer, Richard Meagher, Kamran Rashid, Donna Grabowski, Seema Singhal

Blood (2006) 108 (11): 3040.

https://doi.org/10.1182/blood.V108.11.3040.3040

Published: 2006

Journal Articles

Breakthrough Fungal Infections after Allogeneic Hematopoietic Stem Cell Transplantation in Patients on Prophylactic Voriconazole.

Steve Trifilio, Seema Singhal, Stephanie Williams, Jane Winter, Martin Tallman, Leo Gordon, Olga Frankfurt, Andrew Evens, Jayesh Mehta

Blood (2006) 108 (11): 2849.

https://doi.org/10.1182/blood.V108.11.2849.2849

Published: 2006

Journal Articles

Submyeloablative Allogeneic HSCT for Hematologic Malignancies: Effect of Body Weight.

Seema Singhal, Leo Gordon, Martin Tallman, Jane Winter, Stephanie Williams, Olga Frankfurt, Andrew Evens, Richard Meagher, Lynne Kaminer, David Grinblatt, Jayesh Mehta

Blood (2006) 108 (11): 2949.

https://doi.org/10.1182/blood.V108.11.2949.2949

Published: 2006

Journal Articles

Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId ® (Id/KLH) Vaccine Following Rituximab.

Omer Koc, MD, Charles Redfern, MD, Peter Wiernik, MD, Fred Rosenfelt, MD, Jane Winter, MD, Troy Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas Lin, MD, PhD, Rene Castillo, MD, Nalini Janakiraman, MD, Dan Gold, PhD, John Gutheil, MD, John Bender, PharmD

Blood (2005) 106 (11): 772.

https://doi.org/10.1182/blood.V106.11.772.772

Published: 2005

Journal Articles

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

Owen O’Connor, MD, PhD, John Wright, Craig Moskowitz, MD, Barbara MacGregor-Cortelli, RN, David Straus, MD, Andrew Evans, MD, Jane Winter, MD, Omer Koc, MD, Nancy Horvath, RN, Susan Blumel, MD, Julie Vose, MD, David Schenkein, MD, Andrew Zelenetz, MD

Blood (2004) 104 (11): 607.

https://doi.org/10.1182/blood.V104.11.607.607

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Impact of sequencing of CART vs bi-specific antibody on survival in relapsed/refractory large B-cell lymphoma: An analysis from the ABC consortium

Phase II, single-arm, open-label, multicenter study: Efficacy of adjunctive Bruton's tyrosine kinase inhibitor (BTKi) zanubrutinib and chimeric antigen receptor (CART) in aggressive B-cell non-hodgkins lymphoma (aNHL)

Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium

Bispecific antibody vs non-bispecific antibody systemic therapy as immediate next line treatment after chimeric antigen receptor T-cell (CART) failure in large B-cell lymphoma

Real-world outcomes with bispecific antibody therapies for aggressive B-cell lymphomas in octogenarians

Real world comparison of commercial CAR T-cell constructs for the treatment of LBCL

Outcomes of patients with Relapsed/Refractory aggressive B-cell lymphoma receiving bispecific antibody therapy as monotherapy or in combination with targeted therapy

Socioeconomic disadvantage, as measured by area deprivation index (ADI), impacts survival in patients with relapsed/refractory aggressive lymphoma treated with CART

Tumor-Infiltrating Normal B Lymphocytes Have Remarkable Prognostic Effects and Are Crucial for Antitumor Immune Responses in Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma Has a Low Frequency of dMMR and High Frequencies of DNA Mismatch Repair Protein High Expression Associated with Lower T-Cell Infiltration

Tacrolimus Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients Receiving Concomitant Voriconazole.

Outcome of Relapse after Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) - The Effect of the Underlying Disease on Survival Following Relapse.

Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH) Following Rituximab Induction in Patients (pts) with Follicular B-Cell Lymphoma (FL): Progression Free Survival (PFS) at 4-Year Follow Up.

Submyeloablative Allografts for Hematologic Malignancies: Validation of a Prognostic Model Based on Pre-Transplant Variables.

Reduced-Intesity Allogeneic HSCT in Hematologic Malignancies: Influence of Underlying Diagnosis and Prior Autograft on Outcome.

Breakthrough Fungal Infections after Allogeneic Hematopoietic Stem Cell Transplantation in Patients on Prophylactic Voriconazole.

Submyeloablative Allogeneic HSCT for Hematologic Malignancies: Effect of Body Weight.

Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId ® (Id/KLH) Vaccine Following Rituximab.

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only